Fosun Pharma Wins NMPA Nod for Empagliflozin–Metformin SR Tablets, Targeting China’s USD 674 Million Diabetes Market

Bulletin Express18:06

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) reported that its subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group, has received marketing authorisation from China’s National Medical Products Administration for Empagliflozin and Metformin Hydrochloride Sustained-release Tablets (III).

The dual-therapy tablet, containing 12.5 mg of empagliflozin and 1,000 mg of metformin hydrochloride, is approved as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus already treated with both active ingredients. The product is registered as a Category 3 chemical drug under approval number “Guo Yao Zhun Zi H20265383.”

Fosun Pharma has invested a cumulative RMB 17.92 million in the drug’s development as of June 2026. Market data from IQVIA CHPA indicate that sales of comparable metformin–empagliflozin combinations in mainland China reached roughly RMB 674.00 million in 2025, underscoring the segment’s commercial relevance.

Management noted that the new approval broadens Fosun Pharma’s chronic-disease portfolio, though future sales will depend on factors such as prescription demand, competitive dynamics and distribution coverage.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153794154?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 18:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153794154","market":"hk","top_or_hot":-1,"title":"Fosun Pharma Wins NMPA Nod for Empagliflozin–Metformin SR Tablets, Targeting China’s USD 674 Million Diabetes Market","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) reported that its subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group, has received marketing authorisation from China’s National Medical Products Administration for Empagliflozin and Metformin Hydrochloride Sustained-release Tablets (III).</p>\n<p>The dual-therapy tablet, containing 12.5 mg of empagliflozin and 1,000 mg of metformin hydrochloride, is approved as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus already treated with both active ingredients. The product is registered as a Category 3 chemical drug under approval number “Guo Yao Zhun Zi H20265383.”</p>\n<p>Fosun Pharma has invested a cumulative RMB 17.92 million in the drug’s development as of June 2026. Market data from IQVIA CHPA indicate that sales of comparable metformin–empagliflozin combinations in mainland China reached roughly RMB 674.00 million in 2025, underscoring the segment’s commercial relevance.</p>\n<p>Management noted that the new approval broadens Fosun Pharma’s chronic-disease portfolio, though future sales will depend on factors such as prescription demand, competitive dynamics and distribution coverage.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma Wins NMPA Nod for Empagliflozin–Metformin SR Tablets, Targeting China’s USD 674 Million Diabetes Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma Wins NMPA Nod for Empagliflozin–Metformin SR Tablets, Targeting China’s USD 674 Million Diabetes Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-03 18:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) reported that its subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group, has received marketing authorisation from China’s National Medical Products Administration for Empagliflozin and Metformin Hydrochloride Sustained-release Tablets (III).</p>\n<p>The dual-therapy tablet, containing 12.5 mg of empagliflozin and 1,000 mg of metformin hydrochloride, is approved as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus already treated with both active ingredients. The product is registered as a Category 3 chemical drug under approval number “Guo Yao Zhun Zi H20265383.”</p>\n<p>Fosun Pharma has invested a cumulative RMB 17.92 million in the drug’s development as of June 2026. Market data from IQVIA CHPA indicate that sales of comparable metformin–empagliflozin combinations in mainland China reached roughly RMB 674.00 million in 2025, underscoring the segment’s commercial relevance.</p>\n<p>Management noted that the new approval broadens Fosun Pharma’s chronic-disease portfolio, though future sales will depend on factors such as prescription demand, competitive dynamics and distribution coverage.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1153794154","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153794154","pubTimestamp":1785751613,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) reported that its subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group, has received marketing authorisation from China’s National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药恩格列净-二甲双胍SR片获NMPA批准，瞄准中国6.74亿美元糖尿病市场","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) reported that its subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group, has received marketing authorisation from China’s National Medical Products Administration for Empagliflozin and Metformin Hydrochloride Sustained-release Tablets (III).\nThe dual-therapy tablet, containing 12.5 mg of empagliflozin and 1,000 mg of metformin hydrochloride, is approved as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus already treated with both active ingredients. The product is registered as a Category 3 chemical drug under approval number “Guo Yao Zhun Zi H20265383.”\nFosun Pharma has invested a cumulative RMB 17.92 million in the drug’s development as of June 2026. Market data from IQVIA CHPA indicate that sales of comparable metformin–empagliflozin combinations in mainland China reached roughly RMB 674.00 million in 2025, underscoring the segment’s commercial relevance.\nManagement noted that the new approval broadens Fosun Pharma’s chronic-disease portfolio, though future sales will depend on factors such as prescription demand, competitive dynamics and distribution coverage.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.0","shortVersion":"4.47.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153794154","isCrawlerRequest":true}